Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Sanofi Announced Earlier: Dupixent Approved By European Commission As First And Only Targeted Medicine For Children As Young As Six Months Old With Severe Atopic Dermatitis

By Charles Gross
Today, 8:31 AM
Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis  Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo

SNY

Read More
1 minute read

Sanofi Reported Earlier: Completed XTEND-Kids Phase 3 Study Strengthens Potential Of ALTUVIIIOTM To Redefine Expectations For Treatment Of Children <12 Years Of Age With Hemophilia A; Study Met Primary Endpoint Of Safety

By Charles Gross
Today, 8:31 AM
The XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of ALTUVIIIO as once-weekly prophylaxis in previously treated patients <12 years of age with severe hemophilia A met its primary endpoint of safety, with no FVIII inhibitors detected in 74 children, with more than 50 children experiencing at least 50 exposure days, nearly a full year of treatment.

SNY